A5049350264- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Lung Cancer Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- Venous Thromboembolism Diagnosis and Management
- Radiopharmaceutical Chemistry and Applications
- Pharmacovigilance and Adverse Drug Reactions
- Academic integrity and plagiarism
- Safe Handling of Antineoplastic Drugs
- Urinary and Genital Oncology Studies
- Neutropenia and Cancer Infections
- Prostate Cancer Diagnosis and Treatment
- Biomedical Ethics and Regulation
- HIV/AIDS drug development and treatment
- Long-Term Effects of COVID-19
- Pharmaceutical Economics and Policy
- Pharmaceutical Practices and Patient Outcomes
- HIV/AIDS Research and Interventions
- Drug-Induced Adverse Reactions
- Radiomics and Machine Learning in Medical Imaging
- Central Venous Catheters and Hemodialysis
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2023-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2024
Policlinico S.Orsola-Malpighi
2022
Ospedali Riuniti Marche Nord
2020
University of Bologna
2017
Introduction Anaplastic lymphoma kinase (ALK) inhibitors (ALKi) are the standard treatment for metastatic, ALK-positive non-small cell lung cancer (NSCLC). Second- and third-generation ALKi, including alectinib, brigatinib, ensartinib, envonalkib, lorlatinib, have shown better efficacy than crizotinib. However, due to lack of direct head-to-head comparisons among these agents, optimal metastatic NSCLC remains unclear. Methods This study used IPDfromKM (Individual Patient Data from...
The proven efficacy of mTOR inhibitors (mTORIs), tyrosine kinase (TKIs) or immune checkpoint (ICIs) in metastatic renal cell carcinoma (RCC) suggests that these agents should be investigated as adjuvant therapy with the aim eliminating undetectable microscopic residual disease after curative resection. our study was to compare treatments using an innovative method reconstructing individual patient data. Nine phase III trials describing RCC were selected. IPDfromKM used reconstruct data from...
Background: Patients with locally advanced/metastatic urothelial cancer have been conventionally treated platinum-based chemotherapy. Recently, numerous new treatments proposed to improve overall survival (OS) and reduce adverse effects, but no head-to-head direct comparison is available. Methods: We considered: a) monotherapy immune checkpoint inhibitors (ICI); b) combinations of an ICI chemotherapy; c) other drugs. An indirect was performed identify the regimens most effective in...
48 Background: 68 Ga prostate specific membrane antigen positron emission tomography/computed tomography ( 6 8 Ga-PSMA PET/CT) is a highly sensitive diagnostic tool to detect metastatic sites even at low levels of Prostate Specific Antigen (PSA). We evaluated the impact PET/CT in patients treated with enzalutamide as first-line therapy for mCRPC. Methods: In an observational prospective study, 67 consecutive mCRPC were 160 mg once daily was performed baseline, after 3 months, during...
Background: The proven efficacy of mTOR inhibitors (mTORI), tyrosine kinase (TKI) or immune checkpoint (ICI) therapies in metastatic renal cell carcinoma (RCC), suggested that these agents should be investigated as adjuvant therapy with the aim eliminating any residual undetectable microscopic disease after curative resection. Our study aimed to compare treatments through application an innovative method reconstructs individual patient data. Methods: Nine phase III studies describing...
Investigational drug services need to be organised in a structured approach, especially for sites with large number of ongoing clinical trials. The aim this study was develop tool assess the complexity pharmacy involvement sponsored oncology trial. Categorisation into ordinal categories used trials consistent grant applications. 15 items were divided three sections, and individual item scores agreed upon among four pharmacists experience conduct at two different centres. A final version...
Background: Patients with locally advanced/metastatic urothelial cancer have been conventionally treated platinum-based chemotherapy. Recently, numerous new treatments proposed to improve overall survival (OS) and reduce adverse effects, but no direct head-to-head comparisons among these agents are available. Methods: The evaluated in our analyses included (a) monotherapy immune checkpoint inhibitors (ICI); (b) combinations of an ICI chemotherapy; (c) other drugs. Using OS as the endpoint, a...
Immune checkpoint inhibitors (ICIs) have revolutionised the treatment of metastatic NSCLC and become standard first-line therapy both as monotherapy, for patients with PD-L1 expression ≥50%, in combination chemotherapy (CT), regardless expression. This study used an artificial intelligence technique, IPDfromKM method, to reconstruct individual patient data from Kaplan-Meier curves phase III randomised clinical trial results provide a comparative overview different chemo-immunotherapy...
Background: Immune checkpoint inhibitors (ICIs), either alone or in combination with platinum-based chemotherapy, are effective the first-line treatment of metastatic, non-oncogene addicted, non-small cell lung cancer (NSCLC). However, when NSCLC patients progress, efficacy available options is limited. Methods: We undertook a meta-analysis that compared regimens current standard care. Only randomized controlled trials (RCTs) were included (endpoint, overall survival [OS]). Our analysis used...
Clinical trials offer new and potentially more effective therapeutic options for cancer patients a potential cost-saving opportunity, especially considering that trial drugs are provided free-of-charge. The aim of this study was to analyse drug-related cost savings in clinical institute over 3 year period. relate the pharmaceutical expenditure our centre, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori".We conducted retrospective analysis taking part interventional...
<h3>Background and importance</h3> Cabazitaxel is an antineoplastic agent indicated for the treatment of adult patients with metastatic castration resistant prostate cancer, previously treated a docetaxel containing regimen. The formulation available on market consists vial concentrate which, after dilution, makes 60 mg drug available. recommended dose cabazitaxel 25 mg/m<sup>2</sup> administered every 3 weeks generally doses range from 20 to 50 mg. This results in waste strong economic...
Abstract BACKGROUND AND AIMS Arteriovenous fistula (AVF) must be the first choice where eligible and a prompt approach within 48–72 h should performed in case of acute AVF failure order to maintain patency vascular access. Evaluation most appropriate de-clotting technique made considering patient's comorbidity, characteristics absolute, relative temporary contraindications each kind corrective intervention. The outcome is different between multiple methods nowadays mechanical...
Abstract Background: Routine imaging can be inaccurate, especially in metastatic breast cancer (MBC) with bone-only disease or mainly bone disease. This analysis investigates how the use of whole-body magnetic resonance (WB-MRI), addition to routine computed tomography (CT) and scintigraphy (BS), influence treatment decisions patients known MBC. Methods: In a prospective observational study, our Institute, we performed WB-MRI as baseline follow-up examination (CT, BS) luminal/HER2-negative...
<h3>Background</h3> Regarding therapeutic adherence to new oral anticoagulants (NOAC), several studies<sup>1</sup> have shown lower in dabigatran-treated patients compared rivaroxaban and apixaban. The NOAC introduction has fueled the phenomenon of switching from vitamin K antagonists (VKA) NOAC, vice versa, also other NOAC. <h3>Purpose</h3> aim this descriptive study is evaluate therapy among NOAC-treated by basing analysis on switches, ie passages another or VKA. <h3>Material methods</h3>...
<h3>Background and importance</h3> Tenofovir alafenamide (TAF) is a novel tenofovir prodrug, recently entering the market for HIV infections. TAF results in higher intracellular concentrations of active metabolite diphosphate compared with disoproxil fumarate (TDF), allowing much lower doses versus TDF. This leads to reduction risk kidney bone disease, maintaining same efficacy. <h3>Aim objectives</h3> The aim study was evaluate prescriptive trend TDF based drugs hospital switch from one...